Reversal of collateral ventilation using endoscopic polymer foam in COPD patients undergoing endoscopic lung volume reduction with endobronchial valves: A controlled parallel group trial.
COPD
bronchoscopy and interventional techniques
chronic obstructive pulmonary disease
collateral ventilation
endobronchial valve
endoscopic lung volume reduction
polymer foam
Journal
Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
25
04
2022
accepted:
18
07
2022
pubmed:
3
8
2022
medline:
22
11
2022
entrez:
2
8
2022
Statut:
ppublish
Résumé
We have previously described reversal of collateral ventilation (CV) in a severe chronic obstructive pulmonary disease (COPD) patient with endoscopic polymer foam (EPF), prior to endoscopic lung volume reduction (ELVR) with valves. The aim of this study was to investigate the efficacy of this in a larger cohort and compare outcomes with a similar cohort with no CV. Patients with severe COPD, with the left upper lobe (LUL) targeted for ELVR, were assessed for CV with high resolution computed tomography (HRCT). If fissure completeness was >95% they were enrolled as controls for valves alone (endobronchial valve control group [EBV-CTRL]). If fissure completeness was 80%-95%, defects were mapped to the corresponding segment, where EPF was instilled following confirmation of CV with CHARTIS. EBVs were inserted 1 month afterwards. Fourteen patients were enrolled into both arms. After 6 months, there were significant improvements in both groups in forced expiratory volume in 1 s (FEV1; +19.7% EPF vs. +27.7% EBV-CTRL, p < 0.05); residual volume (RV; -16.2% EPF vs. -20.1% EBV-CTRL, p = NS); SGRQ (-15.1 EPF vs. -16.6 EBV-CTRL p = NS) and 6 min walk (+25.8% EPF [77.2 m] vs. +28.4% [82.3 m] EBV-CTRL p = NS). Patients with fissural defects mapped to the lingula had better outcomes than those mapped to other segments (FEV1 +22.9% vs. +16.3% p < 0.05). There were no serious adverse reactions to EPF. EPF successfully reverses CV in severe COPD patients with a left oblique fissure that is 80%-95% complete. Following EBV, outcomes are similar to patients with complete fissures undergoing ELVR with EBV alone. EPF therapy to reverse CV potentially increases the number of COPD patients suitable for ELVR with minimal adverse reactions.
Sections du résumé
BACKGROUND AND OBJECTIVE
We have previously described reversal of collateral ventilation (CV) in a severe chronic obstructive pulmonary disease (COPD) patient with endoscopic polymer foam (EPF), prior to endoscopic lung volume reduction (ELVR) with valves. The aim of this study was to investigate the efficacy of this in a larger cohort and compare outcomes with a similar cohort with no CV.
METHODS
Patients with severe COPD, with the left upper lobe (LUL) targeted for ELVR, were assessed for CV with high resolution computed tomography (HRCT). If fissure completeness was >95% they were enrolled as controls for valves alone (endobronchial valve control group [EBV-CTRL]). If fissure completeness was 80%-95%, defects were mapped to the corresponding segment, where EPF was instilled following confirmation of CV with CHARTIS. EBVs were inserted 1 month afterwards.
RESULTS
Fourteen patients were enrolled into both arms. After 6 months, there were significant improvements in both groups in forced expiratory volume in 1 s (FEV1; +19.7% EPF vs. +27.7% EBV-CTRL, p < 0.05); residual volume (RV; -16.2% EPF vs. -20.1% EBV-CTRL, p = NS); SGRQ (-15.1 EPF vs. -16.6 EBV-CTRL p = NS) and 6 min walk (+25.8% EPF [77.2 m] vs. +28.4% [82.3 m] EBV-CTRL p = NS). Patients with fissural defects mapped to the lingula had better outcomes than those mapped to other segments (FEV1 +22.9% vs. +16.3% p < 0.05). There were no serious adverse reactions to EPF.
CONCLUSION
EPF successfully reverses CV in severe COPD patients with a left oblique fissure that is 80%-95% complete. Following EBV, outcomes are similar to patients with complete fissures undergoing ELVR with EBV alone. EPF therapy to reverse CV potentially increases the number of COPD patients suitable for ELVR with minimal adverse reactions.
Substances chimiques
Polymers
0
Banques de données
ClinicalTrials.gov
['NCT05396131']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1064-1072Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.
Références
Eur Respir J. 2005 Sep;26(3):511-22
pubmed: 16135736
Respiration. 2011;82(1):36-45
pubmed: 21228545
Respiration. 2019;97(6):548-557
pubmed: 30836374
Eur Respir J. 2005 Oct;26(4):720-35
pubmed: 16204605
N Engl J Med. 2015 Dec 10;373(24):2325-35
pubmed: 26650153
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Lancet. 2015 Sep 12;386(9998):1066-73
pubmed: 26116485
J Bronchology Interv Pulmonol. 2020 Jan;27(1):e14-e16
pubmed: 31856017
Respirology. 2022 Dec;27(12):1064-1072
pubmed: 35918295
Med J Aust. 2021 Sep 20;215(6):280-285
pubmed: 34382211
Respiration. 2019;97(2):145-152
pubmed: 30227420
Respiration. 2016;92(3):150-7
pubmed: 27577190
Eur Respir J. 2015 Sep;46(3):651-62
pubmed: 25837041
Respiration. 2021;100(10):969-978
pubmed: 34062550